Spyre Therapeutics (SYRE) Enterprise Value Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.67% |
| Dec 31, 2025 | -25.80% |
| Sep 30, 2025 | -17.85% |
| Jun 30, 2025 | -23.61% |
| Mar 31, 2025 | -16.19% |
| Dec 31, 2024 | -77.26% |
| Sep 30, 2024 | -102.63% |
| Jun 30, 2024 | -81.00% |
| Mar 31, 2024 | -1,159.53% |
| Dec 31, 2023 | -508.99% |
| Sep 30, 2023 | -176.34% |
| Jun 30, 2023 | -165.79% |
| Mar 31, 2023 | 42.33% |
| Dec 31, 2022 | 40.18% |
| Sep 30, 2022 | 34.47% |
| Jun 30, 2022 | 31.13% |
| Mar 31, 2022 | 47.32% |
| Dec 31, 2021 | 36.33% |
| Sep 30, 2021 | 19.68% |
| Jun 30, 2021 | 18.48% |
| Mar 31, 2021 | -158.53% |
| Dec 31, 2020 | -103.30% |
| Sep 30, 2020 | -57.81% |
| Jun 30, 2020 | -49.45% |
| Mar 31, 2020 | 24.53% |
| Dec 31, 2019 | 3.44% |
| Sep 30, 2019 | -40.79% |
| Jun 30, 2019 | -46.19% |
| Mar 31, 2019 | -60.93% |
| Dec 31, 2018 | -48.14% |
| Sep 30, 2018 | -17.11% |
| Jun 30, 2018 | -13.88% |
| Mar 31, 2018 | 30.30% |
| Dec 31, 2017 | 20.79% |
| Sep 30, 2017 | 20.93% |
| Jun 30, 2017 | 13.84% |
| Mar 31, 2017 | -99.64% |
| Dec 31, 2016 | -92.07% |
| Sep 30, 2016 | -120.61% |
| Jun 30, 2016 | -88.26% |
| Mar 31, 2016 | 33.81% |